Comparison of the Hybrid Capture 2 and cobas 4800 Tests for Detection of High-Risk Human Papillomavirus in Specimens Collected in PreservCyt Medium

ABSTRACT Clinical cervical cytology specimens (n = 466) collected in PreservCyt (Hologic Inc.) were used to evaluate the agreement between Hybrid Capture 2 (hc2; Qiagen) and cobas 4800 (c4800; Roche Molecular Diagnostics) for the detection of high-risk human papillomavirus (HR HPV) genotype infections. The agreement between the two assays was 93.8% (kappa = 0.87; 95% confidence interval, 0.828 to 0.918), with 186 and 251 concordant positive and negative results, respectively. All 186 concordant positives were confirmed using the Linear Array (LA; Roche Molecular Diagnostics) genotyping test. Of the 29 samples with discordant results (6.2%), 18 were hc2 positive and LA verified 17 as positive for HR HPV. Eleven discordant specimens were c4800 positive, and LA confirmed 5 as positive for HR HPV. As of October 2009, practice guidelines in Alberta, Canada, recommend reflex HPV testing for women over 30 years old with atypical squamous cells of undetermined significance (ASCUS) and for women over 50 years old with low-grade squamous intraepithelial lesions (LSIL) to help prioritize those who should undergo further evaluation. In this study, agreement between hc2 and c4800 results for samples from women over 30 years old with ASCUS cytology was 92.3% (n = 13), while no samples from women over 50 years old with LSIL cytology were identified for analysis.

[1]  M. Poljak,et al.  Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. , 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[2]  T. Rohan,et al.  Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. , 2001, JAMA.

[3]  L Beardsley,et al.  Natural history of cervicovaginal papillomavirus infection in young women. , 1998, The New England journal of medicine.

[4]  C. Wheeler,et al.  Human Papillomavirus Genotype Specificity of Hybrid Capture 2 , 2008, Journal of Clinical Microbiology.

[5]  N. Park,et al.  Multiple HPV infection in cervical cancer screened by HPVDNAChip. , 2003, Cancer letters.

[6]  F. X. Bosch,et al.  Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. , 2003, Journal of the National Cancer Institute. Monographs.

[7]  N. Muñoz,et al.  Human papillomavirus infection and invasive cervical cancer in Paraguay , 2000, International journal of cancer.

[8]  H. Cubie,et al.  Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population , 2003, Journal of clinical pathology.

[9]  E. de Villiers,et al.  Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. , 2010, Virology.

[10]  T. Wright,et al.  2006 Consensus Guidelines for the Management of Women With Abnormal Cervical Screening Tests , 2007, Journal of lower genital tract disease.

[11]  M. Lindemann,et al.  Detection of high-risk human papillomavirus by two molecular techniques: hybrid capture and linear array. , 2008, Journal of virological methods.

[12]  H. Cubie,et al.  Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study , 2005, Journal of Clinical Pathology.

[13]  J. Cuzick,et al.  Overview of the European and North American studies on HPV testing in primary cervical cancer screening , 2006, International journal of cancer.

[14]  C. Wheeler,et al.  A Comparison of Linear Array and Hybrid Capture 2 for Detection of Carcinogenic Human Papillomavirus and Cervical Precancer in ASCUS-LSIL Triage Study , 2008, Cancer Epidemiology Biomarkers & Prevention.

[15]  H. Cramer,et al.  Detection of multiple human papillomavirus types in the lower genital tract correlates with cervical dysplasia * ** , 2001, Journal of medical virology.

[16]  J. Berkhof,et al.  Clinical Validation of the cobas 4800 HPV Test for Cervical Screening Purposes , 2011, Journal of Clinical Microbiology.

[17]  S. Garland,et al.  Comparison of the Digene Hybrid Capture 2 Assay and Roche AMPLICOR and LINEAR ARRAY Human Papillomavirus (HPV) Tests in Detecting High-Risk HPV Genotypes in Specimens from Women with Previous Abnormal Pap Smear Results , 2007, Journal of Clinical Microbiology.

[18]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[19]  T. Iftner,et al.  Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients , 2003, British Journal of Cancer.

[20]  Harald zur Hausen,et al.  Papillomaviruses in the causation of human cancers - a brief historical account. , 2009, Virology.

[21]  T. Wright,et al.  High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. , 2011, American journal of clinical pathology.

[22]  J. Sautière,et al.  Persistence and load of high‐risk HPV are predictors for development of high‐grade cervical lesions: A longitudinal French cohort study , 2003, International journal of cancer.

[23]  E. Franco,et al.  Human papillomavirus testing for primary screening of cervical cancer precursors. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[24]  E. Franco,et al.  Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[25]  Francisco A. R. Garcia,et al.  Evaluation of a Prototype Real-Time PCR Assay for Carcinogenic Human Papillomavirus (HPV) Detection and Simultaneous HPV Genotype 16 (HPV16) and HPV18 Genotyping , 2009, Journal of Clinical Microbiology.

[26]  R. Pötter,et al.  Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer , 2002, International journal of cancer.

[27]  Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programmes. , 1986, British medical journal.

[28]  K. Syrjänen,et al.  Detection of Human Papillomavirus Genotypes Among High-Risk Women: A Comparison of Hybrid Capture and Linear Array Tests , 2008, Sexually transmitted diseases.

[29]  C. Wheeler,et al.  Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. , 2006, The Journal of infectious diseases.

[30]  Attila Lorincz,et al.  Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[31]  M. Schiffman,et al.  Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline , 2009, Infectious Agents and Cancer.

[32]  F. Wiklund,et al.  Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. , 1999, The New England journal of medicine.

[33]  R. Richart,et al.  Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. , 2009, Archives of pathology & laboratory medicine.